These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31996496)

  • 1. Conventional and novel impacts of ferric citrate on iron deficiency anemia and phosphorus metabolism in rats.
    Iida A; Matsushita M; Ohta T; Yamada T
    J Vet Med Sci; 2020 Mar; 82(3):379-386. PubMed ID: 31996496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
    Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM
    Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia.
    Ito K; Akizawa T; Arita K; Mitobe Y; Komatsu N
    Clin Exp Nephrol; 2024 Jul; 28(7):636-646. PubMed ID: 38402503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.
    Block GA; Pergola PE; Fishbane S; Martins JG; LeWinter RD; Uhlig K; Neylan JF; Chertow GM
    Nephrol Dial Transplant; 2019 Jul; 34(7):1115-1124. PubMed ID: 30380116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure.
    McCullough PA; Uhlig K; Neylan JF; Pergola PE; Fishbane S
    Am J Cardiol; 2018 Aug; 122(4):683-688. PubMed ID: 29961562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.
    Francis C; Courbon G; Gerber C; Neuburg S; Wang X; Dussold C; Capella M; Qi L; Isakova T; Mehta R; Martin A; Wolf M; David V
    Kidney Int; 2019 Dec; 96(6):1346-1358. PubMed ID: 31668632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Oral Iron Therapies for Iron Deficiency Anemia in Chronic Kidney Disease.
    Pergola PE; Fishbane S; Ganz T
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):272-291. PubMed ID: 31477258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ferric citrate controls phosphorus and delivers iron in patients on dialysis.
    Lewis JB; Sika M; Koury MJ; Chuang P; Schulman G; Smith MT; Whittier FC; Linfert DR; Galphin CM; Athreya BP; Nossuli AK; Chang IJ; Blumenthal SS; Manley J; Zeig S; Kant KS; Olivero JJ; Greene T; Dwyer JP;
    J Am Soc Nephrol; 2015 Feb; 26(2):493-503. PubMed ID: 25060056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of the phosphate binder, ferric citrate hydrate (JTT-751), about phosphorus absorption-reducing effect in normal rats.
    Matsuo A; Iida A; Tanimoto M; Matsushita M; Miyamoto K
    Ren Fail; 2014 Sep; 36(8):1291-7. PubMed ID: 24975675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency.
    Iguchi A; Yamamoto S; Yamazaki M; Tasaki K; Suzuki Y; Kazama JJ; Narita I
    Clin Exp Nephrol; 2018 Aug; 22(4):789-796. PubMed ID: 29181658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of iron replenishment on iron, calcium, phosphorus and magnesium metabolism in iron-deficient rats.
    Pallarés I; López-Aliaga I; Lisbona F; Moratalla A; Gómez-Ayala AE; Barrionuevo M; Hartiti S; Alférez MJ; Campos MS
    Int J Vitam Nutr Res; 1996; 66(2):158-65. PubMed ID: 8843992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a Ferric Citrate Formulation, a Phosphate Binder, on Oxidative Stress in Chronic Kidney Diseases-Mineral and Bone Disorder Patients Receiving Hemodialysis: A Pilot Study.
    Tanaka M; Miyamura S; Imafuku T; Tominaga Y; Maeda H; Anraku M; Yamasaki K; Kadowaki D; Ishima Y; Watanabe H; Okuda T; Itoh K; Matsushita K; Fukagawa M; Otagiri M; Maruyama T
    Biol Pharm Bull; 2016; 39(6):1000-6. PubMed ID: 27251502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Ferric Citrate in Hyperphosphatemia and Iron Deficiency Anemia in Non Dialysis CKD Patients.
    Nand N; Giri K; Jain D
    J Assoc Physicians India; 2019 Apr; 67(4):53-56. PubMed ID: 31311220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD.
    Block GA; Block MS; Smits G; Mehta R; Isakova T; Wolf M; Chertow GM
    J Am Soc Nephrol; 2019 Aug; 30(8):1495-1504. PubMed ID: 31278194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ferric Citrate Attenuates Cardiac Hypertrophy and Fibrosis in a Rat Model of Chronic Kidney Disease.
    Goto M; Suematsu Y; Nunes ACF; Jing W; Khazaeli M; Lau WL; Vaziri ND
    Iran J Kidney Dis; 2019 Mar; 13(2):98-104. PubMed ID: 30988246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency.
    Iguchi A; Kazama JJ; Yamamoto S; Yoshita K; Watanabe Y; Iino N; Narita I
    Nephron; 2015; 131(3):161-6. PubMed ID: 26551233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy of ferric citrate in phosphate-lowering and iron-repletion effects among patients with on hemodialysis: A multicenter, open-label, Phase IV trial.
    Lee CT; Lee CC; Wu MJ; Chiu YW; Leu JG; Wu MS; Peng YS; Wu MS; Tarng DC
    PLoS One; 2022; 17(3):e0264727. PubMed ID: 35239732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enteral ferric citrate absorption is dependent on the iron transport protein ferroportin.
    Hanudel MR; Czaya B; Wong S; Rappaport M; Namjoshi S; Chua K; Jung G; Gabayan V; Qiao B; Nemeth E; Ganz T
    Kidney Int; 2022 Apr; 101(4):711-719. PubMed ID: 34838540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD.
    Biruete A; Metzger CE; Chen NX; Swallow EA; Vrabec C; Clinkenbeard EL; Stacy AJ; Srinivasan S; O'Neill K; Avin KG; Allen MR; Moe SM
    Nephrol Dial Transplant; 2022 Sep; 37(10):1857-1867. PubMed ID: 35482713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification.
    Iida A; Kemmochi Y; Kakimoto K; Tanimoto M; Mimura T; Shinozaki Y; Uemura A; Matsuo A; Matsushita M; Miyamoto K
    Am J Nephrol; 2013; 37(4):346-58. PubMed ID: 23548309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.